Research programme: bacterial topoisomerase inhibitors - Redx Pharma

Drug Profile

Research programme: bacterial topoisomerase inhibitors - Redx Pharma

Alternative Names: NBTIs; REDX06213; REDX06276; REDX07623; REDX08106

Latest Information Update: 27 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Redx Pharma
  • Class Antibacterials; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors; Type II bacterial DNA topoisomerase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 22 Mar 2018 Deinove and Redx enter into option and license agreement for bacterial topoisomerase inhibitors
  • 22 Apr 2017 Efficacy data from a preclinical trial in Bacterial infections presented at the 27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2017) (IV)
  • 16 Jun 2016 Preclinical trials in Bacterial infections in UK before June 2016 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top